M&A and equity raisings
6,065 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds
US deals dated after 30 September 2026 are still being collected.
76 deals · US$54bndisclosed · Life Sciences · Clear
Columns
| Date | Target | Vendor | Acquirer | Type | Status | Value US$m | Sector | Advisers |
|---|---|---|---|---|---|---|---|---|
| Oct 2026 | Rekover Therapeutics | Tenmile | Invex Therapeutics | Acquisition | Announced | – | Healthcare+1 | Moore Australia (buy-side) |
| Sep 2026 | Standard BioTools Mass Cytometry business | Standard BioTools | Element Biosystems | Asset sale | Announced | 5.5 | Life Sciences+1 | Maynard Nexsen (buy-side) |
| Sep 2026 | Lifecore Biomedical | – | Webster Equity Partners | Acquisition | Announced | 663.7 | Pharma Services+2 | Bourne Capital Partners (sell-side)Craig-Hallum (sell-side)Ballard Spahr (sell-side)Zukerman Gore Brandeis & Crossman (sell-side)Morgan Stanley (buy-side)Goodwin (buy-side) |
| Sep 2026 | Agilex Biolabs | Healius | Novotech Health Holdings | Acquisition | Announced | 114.0 | Healthcare+1 | UBS (sell-side)Mallesons (sell-side) |
| Sep 2026 | ITM Isotope Technologies Munich SE | – | Telix Pharmaceuticals | Merger | Announced | 2,350.0 | Healthcare+1 | Latham & Watkins (sell-side)Centerview Partners (sell-side)Morgan Stanley (buy-side)Sidley Austin (buy-side)Herbert Smith Freehills Kramer (buy-side) |
| Sep 2026 | Firma Data Services | Firma Clinical Research | Everest Clinical Research | Asset sale | Completed | – | Clinical Trial Services+1 | Edgemont Partners (sell-side) |
| Sep 2026 | Cellipont Bioservices | – | – | Merger | Completed | – | Pharma Services+2 | William Blair |
| Sep 2026 | Prolytix | Edgewater | VION | Acquisition | Announced | – | Pharma Services+1 | Stout (sell-side) |
| Aug 2026 | Precision Medicine Group | Blackstone | McKesson | Acquisition | Announced | 2,250.0 | Clinical Trial Services+1 | Debevoise & Plimpton (sell-side)Centerview Partners (sell-side)Davis Polk (buy-side) |
| Aug 2026 | Schlafender Hase | – | Maguar Capital | Acquisition | Completed | – | Vertical SaaS+1 | Goodwin (buy-side) |
| Aug 2026 | BWXT Medical business | BWX Technologies | Nordic Capital | Asset sale | Pending | 800.0 | Radiopharmaceuticals+2 | Solomon Partners (sell-side)Stikeman Elliott (sell-side)Kirkland & Ellis (buy-side)McCarthy Tétrault (buy-side) |
| Aug 2026 | South Australian Health and Medical Research Institute (SAHMRI) | Government of South Australia | Adelaide University | Acquisition | Announced | – | Healthcare+1 | HWLE Lawyers (sell-side) |
| Aug 2026 | MIMETAS | – | BRUKER | Acquisition | Completed | – | Life Sciences+1 | Raymond James |
| Aug 2026 | NovaBone Products | Halma | Isto Biologics | Acquisition | Completed | 60.0 | Medtech+1 | Baird (buy-side) |
| Jul 2026 | Avisoft Bioacoustics | – | Lafayette Instrument | Acquisition | Completed | – | Life Sciences+2 | Vedder Price (buy-side)RSM (buy-side) |
| Jul 2026 | MYOS Corp | – | PetIQ | Acquisition | Completed | – | Supplements+2 | Davis Graham (sell-side)Davis Polk (buy-side)Lincoln International (buy-side) |
| Jul 2026 | ArisGlobal | Nordic Capital | Dassault Systèmes | Acquisition | Announced | 2,000.0 | Healthcare Software+2 | Evercore (sell-side)Jefferies (sell-side)Kirkland & Ellis (sell-side)Sullivan & Cromwell (buy-side) |
| Jul 2026 | BioLife Solutions | – | Repligen | Acquisition | Announced | 1,500.0 | Life Sciences+1 | Centerview Partners (sell-side)K&L Gates (sell-side)Goodwin (buy-side)Perella Weinberg Partners (buy-side)Goldman Sachs (buy-side) |
| Jul 2026 | Personalis | – | Tempus AI | Acquisition | Announced | 1,900.0 | Diagnostics+2 | Centerview Partners (sell-side)TD Securities (sell-side)Cooley (sell-side)Morgan Stanley (buy-side)Latham & Watkins (buy-side) |
| Jul 2026 | Life Sciences & Healthcare segment | Clarivate | Altaris | Asset sale | Announced | 600.0 | Healthcare Software+2 | Davis Polk (sell-side)Morgan Stanley (sell-side)Hogan Lovells Cadwalader (sell-side)Joele Frank, Wilkinson Brimmer Katcher (sell-side)Kirkland & Ellis (buy-side) |
| Jul 2026 | DCM BioServices | – | Surplus Solutions | Acquisition | Announced | – | Life Sciences+1 | McDermott Will & Schulte (buy-side) |
| Jul 2026 | GBA Group | Ardian | Bridgepoint | Acquisition | Announced | – | Testing & Inspection+1 | Latham & Watkins (buy-side) |
| Jul 2026 | MeiraGTx Holdings | – | Oberland Capital Management | Stake | Announced | – | Biotech+1 | Latham & Watkins (sell-side) |
| Jul 2026 | Momentum Life Sciences | – | Parthenon Capital Partners | Stake | Completed | – | Healthcare Software+1 | William Blair |
| Jul 2026 | LaCorium Health | founders of LaCorium Health | Prestige Consumer Healthcare | Acquisition | Completed | – | Healthcare+1 | Addisons (sell-side)Pitcher Partners (buy-side) |
| Jul 2026 | B Medical Systems | Azenta | Thelema S.à r.l. | Asset sale | Completed | – | Medtech+1 | William Blair |
| Jun 2026 | Bio-Techne | – | Merck KGaA | Acquisition | Pending | 11,300.0 | Life Sciences+1 | Goldman Sachs (sell-side)Sidley Austin (sell-side)Joele Frank, Wilkinson Brimmer Katcher (sell-side)Guggenheim Securities (buy-side)J.P. Morgan (buy-side)Sullivan & Cromwell (buy-side) |
| Jun 2026 | Sangamo Therapeutics capsid delivery, zinc finger, modular integrase platforms and prion disease program | Sangamo Therapeutics | Eli Lilly and Company | Asset sale | Completed | – | Biotech+1 | Raymond JamesPaul, Weiss (buy-side) |
| Jun 2026 | Simulations Plus | – | Affiliates of Altaris | Acquisition | Announced | 375.0 | Life Sciences+2 | Morgan Stanley (sell-side)Procopio, Cory, Hargreaves & Savitch (sell-side)Bass, Berry & Sims (buy-side)Truist Securities (buy-side)J.P. Morgan (buy-side)Kirkland & Ellis (buy-side)Latham & Watkins (buy-side) |
| Jun 2026 | Ignite Proteomics | Aditxt | Proposed Ignite Proteomics Inc. holding company | Merger | Pending | 150.0 | Life Sciences+2 | Ladenburg Thalmann |
| Jun 2026 | Aspen Pharmacare Asia Pacific business | Aspen Pharmacare Holdings | BGH Capital | Acquisition | Announced | 1,632.2 | Healthcare+1 | Allens (buy-side) |
| Jun 2026 | Kalderos | – | Model N | Acquisition | Announced | – | Healthcare Software+2 | Kirkland & Ellis (buy-side) |
| Jun 2026 | kneat.com | – | Thoma Bravo, L.P. | Acquisition | Pending | 453.6 | Vertical SaaS+1 | Kirkland & Ellis (buy-side) |
| Jun 2026 | Helio Health Group | – | WestView Capital Partners | Stake | Completed | – | AI+1 | Latham & Watkins (buy-side) |
| May 2026 | Ennov Group | – | Bregal Sagemount | Stake | Announced | – | Healthcare Software+2 | Proskauer RoseGoodwin (buy-side) |
| May 2026 | Sutter Instrument Corp. | – | Lafayette Instrument | Acquisition | Completed | – | Manufacturing+2 | EC M&A (sell-side)Donahue Fitzgerald (sell-side)Akerman (buy-side)RSM (buy-side) |
| May 2026 | Regenity Biosciences | – | Cinven | Stake | Announced | – | Medtech+1 | Baird (sell-side) |
| May 2026 | Beacon | Hanson Wade Group | Corten Capital | Acquisition | Announced | – | Market Intelligence+2 | Baird (sell-side) |
| May 2026 | Imexpharm | SK Group | Lian SGP Holding | Acquisition | Announced | – | Healthcare+1 | Allens (sell-side)Linklaters (sell-side) |
| Apr 2026 | XOMA Royalty | – | Ligand Pharmaceuticals | Acquisition | Completed | 739.0 | Specialty finance and leasing+2 | Leerink Partners (sell-side)H.C. Wainwright & Co. (sell-side)Gibson Dunn (sell-side)Stifel (buy-side)Citi (buy-side)Paul Hastings (buy-side)Collected Strategies (buy-side) |
| Apr 2026 | Certara Regulatory and Medical Writing business | Certara | Veristat | Asset sale | Announced | 135.0 | Pharma Services+1 | Perella Weinberg Partners (sell-side)Troutman Pepper Locke (sell-side)Guggenheim Securities (buy-side)McDermott Will & Schulte (buy-side) |
| Apr 2026 | EpiVax | – | SV Health Investors | Acquisition | Announced | – | Pharma Services+2 | Morgan Lewis (buy-side) |
| Apr 2026 | Thermo Fisher Scientific's microbiology division | Thermo Fisher Scientific | Astorg | Asset sale | Announced | 1,075.0 | Diagnostics+1 | Cravath, Swaine & Moore (sell-side)Perella Weinberg Partners (sell-side)Latham & Watkins (buy-side)Moelis & Company (buy-side) |
| Apr 2026 | Accessus Health | shareholders of Ecker + Ecker and Accessus Health | Athagoras | Acquisition | Announced | – | Accounting, legal and consulting+2 | Latham & Watkins (sell-side) |
| Apr 2026 | TriNetX | – | Regeneron Pharmaceuticals | Stake | Completed | – | Healthcare Software+2 | William Blair |
| Apr 2026 | Celerion | H.I.G. Capital affiliate | THL Partners | Acquisition | Announced | – | Pharma Services+2 | LazardKirkland & Ellis (buy-side)Paul, Weiss (buy-side) |
| Mar 2026 | Stratis Group | – | Nexus Health | Acquisition | Announced | – | Accounting, legal and consulting+1 | Clearsight Advisors (sell-side)Pillsbury Winthrop Shaw Pittman (sell-side) |
| Mar 2026 | Biocare Medical | – | Agilent Technologies | Acquisition | Announced | 950.0 | Diagnostics+1 | Sullivan & Cromwell (buy-side) |
| Mar 2026 | UK Biocentre | – | Azenta UK | Acquisition | Completed | 26.9 | Life Sciences+1 | Deloitte (buy-side)Bird & Bird (buy-side) |
| Mar 2026 | Lonza Capsules & Health Ingredients division | Lonza Group AG | Lone Star Funds | Asset sale | Announced | – | Pharmaceutical Manufacturing+2 | Kirkland & Ellis (buy-side) |
Deals come from stock exchange announcements and filings, takeover and scheme documents, prospectuses, the advisers' own deal announcements and the press. How the data is built All countries counts every deal, wherever it is, including deals whose geography is not known.Country pages cover Australia, New Zealand and the United States. The United Kingdom, Canada, Singapore, China and India are planned.